Opinion|Videos|July 1, 2024

Clinical Implications of MajesTEC-1

Author(s)Amrita Y. Krishnan, MD, Binod Dhakal, MD, MS

Amrita Y. Krishnan, MD, and Binod Dhakal, MD, discuss the clinical implications of data from MajesTEC-1 and provide key takeaways on the evolving relapsed/refractory multiple myeloma treatment landscape.

Episodes in this series

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

EP. 1 The Current Treatment Landscape for Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

EP. 2 MajesTEC-1: Efficacy and Safety of Teclistamab

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

EP. 3 Teclistamab Dosing and Adverse Event Prophylaxis Practices

Amrita Y. Krishnan, MD, and Binod Dhakal, MD

EP. 4 Clinical Implications of MajesTEC-1

EP. 5 Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma

EP. 5 Long-Term Data Affirm Enduring Responses With Teclistamab in R/R Multiple Myeloma

Video content above is prompted by the following questions:

Based on the long-term efficacy and safety data presented for teclistamab in the MajesTEC-1 trial, what are your key takeaways or clinical implications for the use of this agent in patients with relapsed/refractory multiple myeloma (R/R MM)?
Despite the promising results with teclistamab, what potential unmet needs or areas for further research and development remain in the treatment of R/R MM?

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Related to this article

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

September 29th, 2026

Where MRD Testing Fits Into Myeloma’s Treatment and Regulatory Landscape

C. Ola Landgren, MD, PhD, discusses the FDA’s endorsement of MRD as an accelerated approval end point in multiple myeloma.

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

September 27th, 2026

Applying the IMS/IMWG Definition of Cure in Community Myeloma Practice

Hans C. Lee, MD, discussed how community oncologists with limited access to MRD testing can think about the new IMS/IMWG definition of cure in myeloma.

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

September 26th, 2026

Managing Sustained MRD Negativity After Multiple Myeloma Therapy Ends

Hans C. Lee, MD, discussed how he monitors patients with multiple myeloma who achieve deep, sustained MRD negativity after coming off therapy.

“[W]e should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

September 25th, 2026

Targeted Agents, Amyloidosis, and Defining a Cure in Plasma Cell Disorders

“We should strive to increase the [number] of patients…who enjoy long-term disease-free survival and possibly cure,” said Meletios Dimopoulos, MD.

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

September 25th, 2026

Sustained MRD Negativity With DVRd Signals Long-Term Survival in NDMM

Pieter Sonneveld, MD, PhD, explained how sustained MRD negativity with DVRd in the PERSEUS trial may guide long-term outcome counseling in multiple myeloma.

Trending on CancerNetwork

EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma

Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery

Multimodal Biopsy Combo Shows Low Morbidity in Suspected Prostate Cancer

FDA OKs Pirtobrutinib in Frontline CLL/SLL

Rectal Spacers May Reduce Toxicity of Proton Therapy in Prostate Cancer